Results 21 to 30 of about 62,912 (312)

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

Annals of the Rheumatic Diseases, 2022
Objectives Recent results from ‘ORAL Surveillance’ trial have raised concerns regarding the cardiovascular safety of tofacitinib in patients with rheumatoid arthritis (RA). We further examined this safety concern in the real-world setting.
F. Khosrow-Khavar, Seoyoung C. Kim, Hemin Lee, Su Been Lee, R. Desai   +4 more
semanticscholar   +1 more source

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

Annals of the Rheumatic Diseases, 2022
Objectives To evaluate malignancies and their associations with baseline risk factors and cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA).
J. Curtis, K. Yamaoka, Yi-Hsing Chen, Deepak L. Bhatt, L. M. Gunay, N. Sugiyama, C. Connell, Cunshan Wang, Joseph Wu, S. Menon, I. Vranic, J. Gómez-Reino   +11 more
semanticscholar   +1 more source

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

Rheumatology and Therapy, 2022
Introduction This post hoc analysis evaluated influenza adverse events (AEs) across rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA) tofacitinib clinical programs. Methods Available data from phase 1, randomized phase 2/3/
Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen   +14 more
doaj   +1 more source

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis

RMD Open, 2022
Objective Post hoc analysis of pooled data from nine randomised controlled trials to assess the effect of tofacitinib (oral Janus kinase inhibitor for treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) on residual pain in patients with
Maxime Dougados, Peter C Taylor, Clifton O Bingham, Lisy Wang, Lara Fallon, Satrajit Roychoudhury, Yves Brault, Meriem Kessouri   +7 more
doaj   +1 more source

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

Possibilities for the use of tofacitinib in patients with COVID-19

Качественная клиническая практика, 2020
No published trials measuring effectiveness of tofacitinib in COVID-19 have been identified. Some professional associations recommend discontinuing tofacitinib if SARS-CoV-2 infections is detected.
A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev   +2 more
doaj   +1 more source

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

Arthritis Research & Therapy, 2022
Background This study examined the time to clinically meaningful response in patients with active psoriatic arthritis treated with tofacitinib, adalimumab, or placebo switching to tofacitinib.
Dafna D. Gladman, Laura C. Coates, Joseph Wu, Lara Fallon, Elizabeth D. Bacci, Joseph C. Cappelleri, Andrew G. Bushmakin, Philip S. Helliwell   +7 more
doaj   +1 more source

Anti-Inflammatory Treatment of COVID-19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2021
Objective: To explore the survival benefit of tofacitinib in addition to dexamethasone in hospitalized patients treated for coronavirus disease 2019 (COVID-19)–related pneumonia.
Maroun E. Hayek, MD, Michael Mansour, MD, Harrison Ndetan, MPH, MD, PhD, Quentin Burkes, PharmD, Robert Corkern, MD, Ammar Dulli, MD, Reya Hayek, BS, Karim Parvez, MD, Satwinder Singh, MD   +8 more
doaj   +1 more source

JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]

, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana, De Schepper, Sofie, Desmet, Eline, Lambert, Jo, Speeckaert, Reinhart, Van Gele, Mireille   +5 more
core   +2 more sources

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

RMD Open, 2021
Background Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib.Methods Data from two trials ...
Roy Fleischmann, Peter C Taylor, Kurt de Vlam, Joseph C Cappelleri, Alexis Ogdie, Lara Fallon, John Woolcott, Valderilio Azevedo, Andrew G Bushmakin   +8 more
doaj   +1 more source